Expert Review of Clinical Immunology 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Malignancies and rheumatoid arthritis, csDMARDs, biological DMARDs, and JAK inhibitors: challenge and outlook
Expert Rev Clin Immunol. 2023 Aug 14:1-18. doi: 10.1080/1744666X.2023.2247158. Online ahead of print.ABSTRACTINTRODUCTION: Rheumatoid arthritis (RA) is an autoimmune disorder necessitating immunosuppressive therapy. Remarkable progress has been made in the treatment of RA over recent decades, particularly with the development of biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (JAKi). Nonetheless, the development of new drugs has been accompanied by concerns regarding the association between these novel therapies and the risk of malignancy.AREAS COVERED: This narrative review aims to d...
Source: Expert Review of Clinical Immunology - August 14, 2023 Category: Allergy & Immunology Authors: Koshiro Sonomoto Yoshiya Tanaka Source Type: research
Neurological adverse effects of chimeric antigen receptor T-cell therapy
Expert Rev Clin Immunol. 2023 Aug 14. doi: 10.1080/1744666X.2023.2248390. Online ahead of print.ABSTRACTINTRODUCTION: Chimeric antigen receptor (CAR) T-cell is among the most prevalent approaches that act by directing T-cells toward cancers; However, they need to be optimized to minimize side effects and maximize efficacy before being used as standard treatment for malignancies. Neurotoxicity associated with CAR T-cell therapy has been well-documented in recent works.AREAS COVERED: In this regard, two established syndromes exist. Immune effector cell-associated neurotoxicity syndrome (ICANS), previously called cytokine rel...
Source: Expert Review of Clinical Immunology - August 14, 2023 Category: Allergy & Immunology Authors: Kiarash Saleki Mohamad Hosein Mohamadi Parsa Alijanizadeh Nima Rezaei Source Type: research
T-lymphocyte depleted transplants for inborn errors of immunity
Expert Rev Clin Immunol. 2023 Aug 9:1-10. doi: 10.1080/1744666X.2023.2245146. Online ahead of print.ABSTRACTINTRODUCTION: Hematopoietic stem cell transplantation is a curative treatment for many inborn errors of immunity (IEI). Incremental improvements and advances in care have led to high rates of >85% survival and cure in many of these diseases. Improvements in HLA-classification and matching have led to increased survival using HLA-matched donors, but survival using T-lymphocyte-depleted mismatched grafts remained significantly worse until fairly recently. Advances in T-lymphocyte depletion methods and graft engineer...
Source: Expert Review of Clinical Immunology - August 9, 2023 Category: Allergy & Immunology Authors: M A Slatter M A Maschan A R Gennery Source Type: research
Direct economic burden 1 year postoperation in Chinese adult patients with chronic rhinosinusitis with nasal polyps
CONCLUSIONS: The individual mean total direct cost of CRSwNP in 1-year post-surgery was $742.4. Clinical control status and asthma comorbidity influence these costs and are therefore important in guiding health resources allocation for CRSwNP management.PMID:37555515 | DOI:10.1080/1744666X.2023.2246660 (Source: Expert Review of Clinical Immunology)
Source: Expert Review of Clinical Immunology - August 9, 2023 Category: Allergy & Immunology Authors: Xian Li Jingyun Li Xu Xu Wenyu She Chengshuo Wang Yuan Zhang Luo Zhang Source Type: research
T-lymphocyte depleted transplants for inborn errors of immunity
Expert Rev Clin Immunol. 2023 Aug 9:1-10. doi: 10.1080/1744666X.2023.2245146. Online ahead of print.ABSTRACTINTRODUCTION: Hematopoietic stem cell transplantation is a curative treatment for many inborn errors of immunity (IEI). Incremental improvements and advances in care have led to high rates of >85% survival and cure in many of these diseases. Improvements in HLA-classification and matching have led to increased survival using HLA-matched donors, but survival using T-lymphocyte-depleted mismatched grafts remained significantly worse until fairly recently. Advances in T-lymphocyte depletion methods and graft engineer...
Source: Expert Review of Clinical Immunology - August 9, 2023 Category: Allergy & Immunology Authors: M A Slatter M A Maschan A R Gennery Source Type: research
Direct economic burden 1 year postoperation in Chinese adult patients with chronic rhinosinusitis with nasal polyps
CONCLUSIONS: The individual mean total direct cost of CRSwNP in 1-year post-surgery was $742.4. Clinical control status and asthma comorbidity influence these costs and are therefore important in guiding health resources allocation for CRSwNP management.PMID:37555515 | DOI:10.1080/1744666X.2023.2246660 (Source: Expert Review of Clinical Immunology)
Source: Expert Review of Clinical Immunology - August 9, 2023 Category: Allergy & Immunology Authors: Xian Li Jingyun Li Xu Xu Wenyu She Chengshuo Wang Yuan Zhang Luo Zhang Source Type: research
T-lymphocyte depleted transplants for inborn errors of immunity
Expert Rev Clin Immunol. 2023 Aug 9:1-10. doi: 10.1080/1744666X.2023.2245146. Online ahead of print.ABSTRACTINTRODUCTION: Hematopoietic stem cell transplantation is a curative treatment for many inborn errors of immunity (IEI). Incremental improvements and advances in care have led to high rates of >85% survival and cure in many of these diseases. Improvements in HLA-classification and matching have led to increased survival using HLA-matched donors, but survival using T-lymphocyte-depleted mismatched grafts remained significantly worse until fairly recently. Advances in T-lymphocyte depletion methods and graft engineer...
Source: Expert Review of Clinical Immunology - August 9, 2023 Category: Allergy & Immunology Authors: M A Slatter M A Maschan A R Gennery Source Type: research
Direct economic burden 1 year postoperation in Chinese adult patients with chronic rhinosinusitis with nasal polyps
CONCLUSIONS: The individual mean total direct cost of CRSwNP in 1-year post-surgery was $742.4. Clinical control status and asthma comorbidity influence these costs and are therefore important in guiding health resources allocation for CRSwNP management.PMID:37555515 | DOI:10.1080/1744666X.2023.2246660 (Source: Expert Review of Clinical Immunology)
Source: Expert Review of Clinical Immunology - August 9, 2023 Category: Allergy & Immunology Authors: Xian Li Jingyun Li Xu Xu Wenyu She Chengshuo Wang Yuan Zhang Luo Zhang Source Type: research
T-lymphocyte depleted transplants for inborn errors of immunity
Expert Rev Clin Immunol. 2023 Aug 9:1-10. doi: 10.1080/1744666X.2023.2245146. Online ahead of print.ABSTRACTINTRODUCTION: Hematopoietic stem cell transplantation is a curative treatment for many inborn errors of immunity (IEI). Incremental improvements and advances in care have led to high rates of >85% survival and cure in many of these diseases. Improvements in HLA-classification and matching have led to increased survival using HLA-matched donors, but survival using T-lymphocyte-depleted mismatched grafts remained significantly worse until fairly recently. Advances in T-lymphocyte depletion methods and graft engineer...
Source: Expert Review of Clinical Immunology - August 9, 2023 Category: Allergy & Immunology Authors: M A Slatter M A Maschan A R Gennery Source Type: research
Direct economic burden 1 year postoperation in Chinese adult patients with chronic rhinosinusitis with nasal polyps
CONCLUSIONS: The individual mean total direct cost of CRSwNP in 1-year post-surgery was $742.4. Clinical control status and asthma comorbidity influence these costs and are therefore important in guiding health resources allocation for CRSwNP management.PMID:37555515 | DOI:10.1080/1744666X.2023.2246660 (Source: Expert Review of Clinical Immunology)
Source: Expert Review of Clinical Immunology - August 9, 2023 Category: Allergy & Immunology Authors: Xian Li Jingyun Li Xu Xu Wenyu She Chengshuo Wang Yuan Zhang Luo Zhang Source Type: research
Why do drug treatments fail in Sj ögren's disease? Considerations for treatment, trial design and interpretation of clinical efficacy
Expert Rev Clin Immunol. 2023 Aug 8:1-8. doi: 10.1080/1744666X.2023.2234641. Online ahead of print.ABSTRACTINTRODUCTION: Despite ongoing efforts to develop effective therapeutics, no disease-modifying drugs have been officially licensed for the indication of Sjögren's disease (SjD). This is partly due to heterogeneity in disease manifestations, which complicates drug target selection, trial design and interpretation of clinical efficacy in SjD.AREAS COVERED: Here, we summarize developments and comment on challenges in 1) identifying the right target for treatment, 2) selection of the primary study endpoint for trials and ...
Source: Expert Review of Clinical Immunology - August 8, 2023 Category: Allergy & Immunology Authors: Suzanne Arends Gwenny M Verstappen Liseth de Wolff Sarah Pringle Frans G M Kroese Arjan Vissink Hendrika Bootsma Source Type: research
COVID-19 and chronic rhinosinusitis: management and comorbidity - what have we learned?
Expert Rev Clin Immunol. 2023 Aug 8. doi: 10.1080/1744666X.2023.2244673. Online ahead of print.ABSTRACTINTRODUCTION: Approximately 5-12% of the population worldwide suffer from chronic rhinosinusitis (CRS). CRS is defined as a chronic respiratory disease and is considered to be a risk factor for COVID-19 patients.AREAS COVERED: A non-systematic literature research was conducted on COVID-19 and treatment options for CRSwNP. Latest international publications in medical databases, international guidelines, and the internet were reviewed. Since there were no publications on all aspects of this topic during the pandemic, we inc...
Source: Expert Review of Clinical Immunology - August 8, 2023 Category: Allergy & Immunology Authors: L Klimek J Hagemann T Huppertz F B ärhold T Albrecht F Klimek I Casper M Cuevas C Bergmann S Becker Source Type: research
Why do drug treatments fail in Sj ögren's disease? Considerations for treatment, trial design and interpretation of clinical efficacy
Expert Rev Clin Immunol. 2023 Aug 8. doi: 10.1080/1744666X.2023.2234641. Online ahead of print.ABSTRACTINTRODUCTION: Despite ongoing efforts to develop effective therapeutics, no disease-modifying drugs have been officially licensed for the indication of Sjögren's disease (SjD). This is partly due to heterogeneity in disease manifestations, which complicates drug target selection, trial design and interpretation of clinical efficacy in SjD.AREAS COVERED: Here, we summarize developments and comment on challenges in 1) identifying the right target for treatment, 2) selection of the primary study endpoint for trials and defi...
Source: Expert Review of Clinical Immunology - August 8, 2023 Category: Allergy & Immunology Authors: Suzanne Arends Gwenny M Verstappen Liseth de Wolff Sarah Pringle Frans G M Kroese Arjan Vissink Hendrika Bootsma Source Type: research
COVID-19 and chronic rhinosinusitis: management and comorbidity - what have we learned?
Expert Rev Clin Immunol. 2023 Aug 8. doi: 10.1080/1744666X.2023.2244673. Online ahead of print.ABSTRACTINTRODUCTION: Approximately 5-12% of the population worldwide suffer from chronic rhinosinusitis (CRS). CRS is defined as a chronic respiratory disease and is considered to be a risk factor for COVID-19 patients.AREAS COVERED: A non-systematic literature research was conducted on COVID-19 and treatment options for CRSwNP. Latest international publications in medical databases, international guidelines, and the internet were reviewed. Since there were no publications on all aspects of this topic during the pandemic, we inc...
Source: Expert Review of Clinical Immunology - August 8, 2023 Category: Allergy & Immunology Authors: L Klimek J Hagemann T Huppertz F B ärhold T Albrecht F Klimek I Casper M Cuevas C Bergmann S Becker Source Type: research
A review of genetic risk in systemic lupus erythematosus
Expert Rev Clin Immunol. 2023 Jul 26:1-12. doi: 10.1080/1744666X.2023.2240959. Online ahead of print.ABSTRACTINTRODUCTION: Systemic Lupus Erythematosus (SLE) is a complex multisystem autoimmune disease with a wide range of signs and symptoms in affected individuals. The utilization of genome-wide association study (GWAS) technology has led to an explosion in the number of genetic risk factors mapped for autoimmune diseases, including SLE.AREAS COVERED: In this review, we summarize the more recent genetic risk loci mapped in SLE, which bring the total number of loci mapped to approximately 200. We review prioritization anal...
Source: Expert Review of Clinical Immunology - July 27, 2023 Category: Allergy & Immunology Authors: Suri Guga Yuxuan Wang Deborah Cunninghame Graham Timothy J Vyse Source Type: research
